The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

avigenics.com

Stage

Grant | Alive

Total Raised

$25.57M

Last Raised

$100K | 15 yrs ago

About AviGenics

Avigenics is a company that received a SBIR Phase I grant for a project entitled: Production of Transgenic Poultry Resistant to Avian Influenza Infection by RNAi. Their project generates transgenic poultry resistant to avian influenza (AI) virus through RNA interference (RNAi) technology. Poultry are vulnerable to AI infections that can rapidly reach mortality rates approaching 100%. Current vaccines provide only limited protection, with prophylaxis based on surveillance and diagnosis, followed by rapid depopulation and disposal of infected or exposed birds and quarantine and disinfection of farms and equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), (ii) establish stable cell lines hosting siRNAs vectors and (iii) test the efficacy of siRNAs against AI viruses. Three siRNAs shown to effectively inhibit AI viruses will be used to generate cell lines, which will be challenged with 5 different AI viruses to determine whether these vectors, when integrated into the avian genome, can effectively inhibit AI viruses. The broader impact of this research will be to improve the biosecurity of biopharmaceutical production in poultry as the avian influenza virus spreads and well as potentially protecting the food supply from natural as well as bioterrorist threats should these transgenic chickens gain wide approval in the marketplace.

AviGenics Headquarter Location

111 Riverbend Rd.

Athens, Georgia, 30605,

United States

706-227-1170

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

AviGenics Patents

AviGenics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2007

3/24/2009

Molecular biology, Biotechnology, Genetics, RNA, Molecular biology techniques

Grant

Application Date

1/4/2007

Grant Date

3/24/2009

Title

Related Topics

Molecular biology, Biotechnology, Genetics, RNA, Molecular biology techniques

Status

Grant

Latest AviGenics News

Synageva BioPharma Corp. formerly AviGenics Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 26, 2016

Advertisement Topics   Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 13:48 EST 26 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Project Synopsis: Datamonitor's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Project Description: Datamonitors' Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc. since January 2007. Scope: Provides intelligence on Synageva BioPharma Corp. formerly AviGenics, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Synageva BioPharma Corp. formerly AviGenics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. Highlights: This report includes Synageva BioPharma Corp. formerly AviGenics, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed. The profile also includes detailed deal reports for all MA, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed. Reasons to Purchase: Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Synageva BioPharma Corp. formerly AviGenics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

You May Also Like

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Pulmotect Logo
Pulmotect

Pulmotect is a biopharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.

Biolog Logo
Biolog

Biolog, Inc. is a company that began operations in 1984. The company's product lines have been built upon patented technology that greatly aims to simplify testing of cells. Biolog's first products were introduced in 1988 and by 1990 it had established a profitable growing business in microbiology for the identification and characterization of microbial cells. In 1991, Biolog, Inc. was a recipient of the "R&D 100 Award" for the company's groundbreaking bacterial identification products. These products, marketed under the MicroLog, MicroStation and OmniLog brand names, are sold worldwide through direct sales as well as distribution. The principal customers of the company's microbiology identification products are laboratories needing capabilities, especially pharmaceutical, biotech, cosmetics, and medical device companies, university and government research laboratories, labs testing for diseases in animals and plants, labs performing environmental monitoring, and companies or organizations involved in production or testing of food and drink. From this technology base in 1999 and with an SBIR award from the National Institutes for Health Human Genome Research Institute, Biolog began development of its Phenotype MicroArray technology. This technology aims to allow researchers to evaluate thousands of cellular phenotypes simultaneously in both microbial and mammalian cells. Development of array sets testing 2,000 phenotypes of microbial cells was completed and first introduced in September 2001. Now Phenotype MicroArray technology is being tested under license in many pharmaceutical and biotechnology companies for use in drug and enzyme development programs. Biolog continues to develop and patent technologies that allow scientists to broadly characterize cellular functions using arrays of phenotypic tests. In addition to revenue from product sales, Biolog has received funding from private investments and Small Business Innovation Research (SBIR) grants and contracts from the National Institutes for Health (NIH), Department of Energy (DOE), National Aeronautics and Space Administration (NASA) and the National Science Foundation (NSF).

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

F
Futropha

Futropha has developed a antibody production platform based on a bacterium called Ralstonia eutropha. This expression platform offers a method of antibody production that is inherently more cost-effective and scalable than current production methods. The company aim to use this technology to provide antibodies to biotechnology companies for preclinical and clinical research.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.